{
    "Trade/Device Name(s)": [
        "Liquichek Whole Blood Immunosuppressant Control"
    ],
    "Submitter Information": "Bio-Rad Laboratories",
    "510(k) Number": "K121143",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072721"
    ],
    "Regulatory Class": "Class I, Reserved",
    "Product Code(s)": [
        "DIF"
    ],
    "Summary Letter Date": "April 12, 2012",
    "Summary Letter Received Date": "April 16, 2012",
    "Submission Date": "May 17, 2012",
    "Regulation Number(s)": [
        "21 CFR 862.3280"
    ],
    "Regulation Name(s)": [
        "Quality Control Material (Assayed and Unassayed)"
    ],
    "Analyte Class(es)": [
        "tdm",
        "transplant",
        "chemistry"
    ],
    "Analyte(s)": [
        "Cyclosporine",
        "Tacrolimus",
        "Sirolimus",
        "Everolimus"
    ],
    "Specimen Type(s)": [
        "Whole Blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Liquichek Whole Blood Immunosuppressant Control assayed quality control material for immunosuppressant drugs in whole blood",
    "Indications for Use Summary": "Intended for use as an assayed quality control material to monitor the precision of laboratory testing procedures for Cyclosporine, Tacrolimus, Sirolimus, and Everolimus in whole blood",
    "fda_folder": "Toxicology"
}